ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

ADMA Biologics (ADMA) is back in focus after updating its 2026 revenue and adjusted EBITDA outlook and withdrawing its longer term guidance, as investors weigh strong ASCENIV growth against pressure in BIVIGAM.

See our latest analysis for ADMA Biologics.

The updated 2026 outlook and withdrawn longer term guidance have coincided with sharp share price pressure, with the stock down 55% year to date and the 1 year total shareholder return declining 61%, even though the 5 year total shareholder return is up more than 3x.

If you are reassessing your exposure to healthcare and biotech after this guidance reset, it can be useful to compare ADMA with other opportunities in the space using a dedicated screener such as 39 healthcare AI stocks.

With ADMA Biologics now valued at around US$1.85b and trading well below some analyst price targets, the key question for you is whether recent setbacks create a buying opportunity or whether the market already reflects future growth.

Most Popular Narrative: 57% Undervalued

At a last close of $7.98 versus a narrative fair value of about $18.33, the most followed storyline around ADMA Biologics sees a large gap between price and what future cash generation could justify, based on discounted earnings and margin assumptions that stretch out to 2029.

Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.

Read the complete narrative.

Curious what sits behind that expected margin lift and earnings path? The narrative leans heavily on compounding revenue, rising profitability, and a future valuation multiple that is not extreme for profitable biotechs. The full set of forecasts spells out how those moving parts combine into an $18+ fair value.

Result: Fair Value of $18.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat story still runs into real friction if reliance on ASCENIV and BIVIGAM, or any disruption in the yield enhancement process, weakens the earnings path that analysts expect.

Find out about the key risks to this ADMA Biologics narrative.

Next Steps

Given the mix of optimism and concern in this story, it makes sense to move quickly. Test the numbers yourself and decide where you stand, especially by checking the 3 key rewards.

Story Continues

Looking for more investment ideas?

If ADMA no longer feels like the whole story for your portfolio, broaden your watchlist now so you are not relying on a single healthcare stock.

Target income first by scanning companies labelled as 10 dividend fortresses that may align with your cash flow goals. Hunt for potential mispriced opportunities using the screener containing 22 high quality undiscovered gems that focus on companies with strong fundamentals yet limited attention. Prioritise resilience by reviewing the 64 resilient stocks with low risk scores that spotlight businesses with steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ADMA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments